71,990 Shares in Fate Therapeutics, Inc. (FATE) Acquired by Teachers Advisors LLC

Teachers Advisors LLC purchased a new position in Fate Therapeutics, Inc. (NASDAQ:FATE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 71,990 shares of the biopharmaceutical company’s stock, valued at approximately $233,000. Teachers Advisors LLC owned approximately 0.17% of Fate Therapeutics as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in FATE. KCG Holdings Inc. lifted its stake in Fate Therapeutics by 7.8% in the 1st quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 1,764 shares in the last quarter. Rhumbline Advisers purchased a new stake in Fate Therapeutics in the 2nd quarter worth $133,000. Schwab Charles Investment Management Inc. purchased a new stake in Fate Therapeutics in the 2nd quarter worth $214,000. Bank of New York Mellon Corp lifted its stake in Fate Therapeutics by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 59,510 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 952 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in Fate Therapeutics in the 2nd quarter worth $331,000. Institutional investors and hedge funds own 63.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “71,990 Shares in Fate Therapeutics, Inc. (FATE) Acquired by Teachers Advisors LLC” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/11/21/71990-shares-in-fate-therapeutics-inc-fate-acquired-by-teachers-advisors-llc.html.

Several analysts have commented on FATE shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, October 12th. Leerink Swann reiterated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Friday, September 8th. Zacks Investment Research cut shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. ValuEngine cut shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Fate Therapeutics has an average rating of “Buy” and a consensus price target of $6.79.

Shares of Fate Therapeutics, Inc. (NASDAQ FATE) opened at $4.39 on Tuesday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics, Inc. has a 1 year low of $2.40 and a 1 year high of $5.68.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The business’s revenue for the quarter was up .0% on a year-over-year basis. equities research analysts forecast that Fate Therapeutics, Inc. will post -0.99 earnings per share for the current year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is currently owned by corporate insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATE).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply